SCHEMBL276038

SCHEMBL276038

c1ccc(-c2ccc(-c3c4ccccc4c(-c4cccc5ccccc45)c4ccc(-c5ccccn5)cc34)cc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.46
KDM4E B2RXH2 2/20 0.46
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
DHODH Q02127 2/20 0.44
HTR2C P28335 2/20 0.43
TGFBR1 P36897 1/20 0.43
DCTPP1 Q9H773 1/20 0.43
PDK2 Q15119 1/20 0.39
PRMT5 O14744 2/20 0.38
WDR77 Q9BQA1 1/20 0.38
ENPP3 O14638 1/20 0.38
ENPP1 P22413 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10030061 0.93 MAPK1 (0.47) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL9612929 0.93 KDM4E (0.51) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL24353135 0.91 MAPK1 (0.45) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL18563322 0.90 HSD17B10 (0.44) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL15977590 0.90 KDM4E (0.44) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL2620618 0.89 TGFBR1 (0.40) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL15977842 0.89 KDM4E (0.49) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL16455823 0.88 ALDH1A1 (0.43) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL10030063 0.88 KDM4E (0.45) MAPK1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL17227627 0.88 KDM4E (0.47) MAPK1KDM4ETP53SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME AKR7A2, ACMSD, ALKBH3 MAPK1 3650/4885KDM4E 2577/4885TP53 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.